2 results
Approved WMOCompleted
The aim of this study is to collect data in a structured way in order to explore the tolerability, safety and efficacy of paliperiode ER with treatment schedules which will be used in future clinical practice.
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.